JP2016502974A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502974A5
JP2016502974A5 JP2015545914A JP2015545914A JP2016502974A5 JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5 JP 2015545914 A JP2015545914 A JP 2015545914A JP 2015545914 A JP2015545914 A JP 2015545914A JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5
Authority
JP
Japan
Prior art keywords
gdc
combination
cancer
acceptable salt
mehd7945a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015545914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/073914 external-priority patent/WO2014089570A1/en
Publication of JP2016502974A publication Critical patent/JP2016502974A/ja
Publication of JP2016502974A5 publication Critical patent/JP2016502974A5/ja
Pending legal-status Critical Current

Links

JP2015545914A 2012-12-07 2013-12-09 Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 Pending JP2016502974A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734796P 2012-12-07 2012-12-07
US61/734,796 2012-12-07
US201361888892P 2013-10-09 2013-10-09
US61/888,892 2013-10-09
PCT/US2013/073914 WO2014089570A1 (en) 2012-12-07 2013-12-09 Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder

Publications (2)

Publication Number Publication Date
JP2016502974A JP2016502974A (ja) 2016-02-01
JP2016502974A5 true JP2016502974A5 (cg-RX-API-DMAC7.html) 2016-12-15

Family

ID=49885413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545914A Pending JP2016502974A (ja) 2012-12-07 2013-12-09 Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用

Country Status (11)

Country Link
US (1) US9566334B2 (cg-RX-API-DMAC7.html)
EP (1) EP2928488A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016502974A (cg-RX-API-DMAC7.html)
KR (1) KR20150092760A (cg-RX-API-DMAC7.html)
CN (1) CN104968363A (cg-RX-API-DMAC7.html)
BR (1) BR112015013196A2 (cg-RX-API-DMAC7.html)
CA (1) CA2894153A1 (cg-RX-API-DMAC7.html)
HK (1) HK1211218A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015007054A (cg-RX-API-DMAC7.html)
RU (1) RU2015127037A (cg-RX-API-DMAC7.html)
WO (1) WO2014089570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2959014B1 (en) * 2013-02-25 2019-11-13 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
PE20090678A1 (es) * 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
BR112013025397A2 (pt) * 2011-04-01 2019-09-24 Deepak Sampath combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
WO2012177925A1 (en) * 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
WO2013075059A1 (en) * 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
WO2013086031A1 (en) * 2011-12-05 2013-06-13 Nestec S.A. Method of therapy selection for patients with cancer

Similar Documents

Publication Publication Date Title
JP2014509659A5 (cg-RX-API-DMAC7.html)
JP2014512354A5 (cg-RX-API-DMAC7.html)
JP2014512356A5 (cg-RX-API-DMAC7.html)
RU2013148728A (ru) Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения
MX2021002321A (es) Nuevos metodos.
JP2014512355A5 (cg-RX-API-DMAC7.html)
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2014509657A5 (cg-RX-API-DMAC7.html)
RU2012156903A (ru) Способы комбинированной терапии для лечения пролиферативных заболеваний
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
JP2016528162A5 (cg-RX-API-DMAC7.html)
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
JP2015512398A5 (cg-RX-API-DMAC7.html)
RU2016141569A (ru) Комбинации
PH12017501580A1 (en) Antibody drug conjugates (adc) that bind to flt3 proteins
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
PH12015500392A1 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
Kleibeuker et al. Combining radiotherapy with sunitinib: lessons (to be) learned
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
RU2018138626A (ru) Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
RU2015138576A (ru) Комбинации соединения ингибитора мек с соединением ингибитором her3/egfr и способы применения
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение